Naratriptan (Amerge) vs Rizatriptan (Maxalt)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline
Naratriptan (Amerge)
Rights held by GlaxoSmithKline; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Rizatriptan (Maxalt)
Marketed by Organon
NCT00897949 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial, and both rizatriptan doses significantly increased pain relief at 2 hours compared with placebo. The sources available for this trial do not report a sample-size calculation or a planned enrolment, so it cannot be confirmed that the trial was adequately powered.
Reported efficacy
Pain Relief at 2 Hours After the Initial Dose of Test Drug (2 hours after initial dose of test drug): Pain relief at 2 hours after the first dose: rizatriptan 5 mg 62% (285/457) and 10 mg 71% (322/455) vs placebo 35% (106/302), significantly higher for both doses (Teall et al., Headache 1998; CT.gov posted counts). (met)
Result source: NCT00897949
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Naratriptan (Amerge): no structured comparison results are available for Migraine.
Rizatriptan (Maxalt): registry results are on file for Migraine, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Naratriptan (Amerge)'s landscape · Rizatriptan (Maxalt)'s landscape